Published in Cancer Weekly, December 30th, 2003
MLN2704 is currently being evaluated in a phase I/II clinical trial at Memorial Sloan-Kettering Cancer Center and New York-Presbyterian Hospital/Weill Cornell Medical Center for the treatment of patients with metastatic androgen-independent prostate cancer.
"We are pleased that the FDA has recognized the critical situation shared by men who suffer from hormone refractory prostate cancer," said David Schenkein, MD, vice president, clinical oncology development, Millennium....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.